The names of 53 distinguished individuals elected to become Fellows of the Royal Society of Edinburgh (RSE) were announced on 5 March. These outstanding people come from a wide variety of disciplines, spanning the arts, business, science and technology sectors. They join Fellows, past and present, who have strived to attain the RSE’s founding mission: ‘the advancement of learning and useful knowledge’.
Amongst these Fellows is Professor Andrew Jackson, a Programme Leader at the MRC Human Genetics Unit in the MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh.
Also elected as a Fellow is Professor Sarah Cunningham-Burley, Head of the School of Molecular, Genetic and Population Health Sciences at The University of Edinburgh.
Congratulations to both Professors Jackson and Cunningham-Burley on becoming Fellows of the Royal Society of Edinburgh.
A team of researchers, including Professor David FitzPatrick from the MRC Human Genetics Unit at the IGMM, have identified genetic changes linked to coloboma, a malformation of the eye which affects around one in every 5,000 births.
A gene known as YAP1 was found not to be working in some patients and led to the disease. Researcher David FitzPatrick, explained: ““Everyone has got two copies of each gene. Individuals who have got these genetic changes have got one copy of the YAP1 gene that works and one that doesn’t work. This is the first time anyone has identified any change in YAP1 which causes human disease.”
The research is featured in the Scotland on Sunday (26 January 2014).
Cancer patients could one day experience fewer side effects from chemotherapy following a discovery that opens the door for more targeted treatments.
Researchers from the MRC Institute of Genetics and Molecular Medicine have identified a possible way of treating tumours that would see doctors place harmless metal implants at the cancer site.
The discovery could make treatment more targeted than existing therapies, avoiding unwanted side effects, such as hair loss, tiredness and nausea. These occur when chemotherapy drugs carried in the blood kill healthy cells as well as cancer cells.